AMPH — Amphastar Pharmaceuticals Cashflow Statement
0.000.00%
- $1.15bn
- $1.53bn
- $731.97m
- 91
- 90
- 45
- 89
Annual cashflow statement for Amphastar Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | 1.1 | 63.3 | 91.4 | 138 | 160 |
Depreciation | |||||
Amortisation | |||||
Deferred Taxes | |||||
Non-Cash Items | 22 | 7.48 | 17.7 | 41 | 29.1 |
Unusual Items | |||||
Equity in Net Earnings/Losses | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 9.13 | -1.92 | -32.2 | -24.2 | -14.5 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Prepaid Expenses | |||||
Change in Payable / Accrued Expenses | |||||
Change in Taxes Payable | |||||
Net Change in Other Assets & Liabilities | |||||
Cash from Operating Activities | 57.3 | 98 | 89.2 | 184 | 213 |
Capital Expenditures | -33.9 | -27.5 | -24 | -38.2 | -41 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | -2.56 | -1.22 | -8.74 | -611 | -83.9 |
Acquisition of Business | |||||
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Change in Net Investments | |||||
Purchase of Investments | |||||
Cash from Investing Activities | -36.4 | -28.7 | -32.8 | -649 | -125 |
Financing Cash Flow Items | -0.106 | -56.2 | -0.407 | -25.1 | -0.816 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | -2.25 | -37 | -26.4 | 454 | -81 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 19 | 32.1 | 29.7 | -11.8 | 7.31 |